Subject(s)

Betacoronavirus , Coronavirus Infections/complications , Lung Neoplasms/complications , Pandemics , Pneumonia, Viral/complications , Age Factors , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , COVID-19 , Carcinoma, Bronchogenic/complications , Carcinoma, Bronchogenic/drug therapy , Carcinoma, Bronchogenic/epidemiology , Carcinoma, Bronchogenic/surgery , Combined Modality Therapy , Comorbidity , Coronavirus Infections/epidemiology , Critical Care , Disease Management , Hospital Mortality , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/epidemiology , Lung Neoplasms/surgery , Pneumonectomy , Pneumonia, Viral/epidemiology , Prognosis , Retrospective Studies , Risk , SARS-CoV-2 , Time-to-Treatment

Subject(s)

Betacoronavirus , Coronavirus Infections/epidemiology , Lung Neoplasms/surgery , Pneumonia, Viral/epidemiology , Practice Guidelines as Topic , Waiting Lists , COVID-19 , Coronavirus Infections/diagnosis , Humans , Pandemics , Pneumonia, Viral/diagnosis , SARS-CoV-2 , Societies, Medical , Triage , Withholding Treatment